Manuel Lizasoain

TL;DR: In the absence of an apparent predictor of the development of disseminated BCG infection after intravesical therapy, and considering the protean variety of clinical manifestations, it is essential to keep a high index of suspicion to initiate adequate therapy promptly and to evaluate carefully the risk-benefit balance of resuming intravesicals BCG immunotherapy.

TL;DR: Unrecognized bacteremia in the donor does not have a negative clinical impact on the outcome of organ transplant recipients and there were no documented instances of transmission of the isolated bacteria from the donor to the recipient.

TL;DR: Severe LI occurs in a subgroup of high‐risk SOT recipients who deserve a more careful follow-up and could benefit from prolonged prophylactic measures similar to that performed in the early period after transplantation.

TL;DR: No differences in renal function prognosis between patients who do not develop asymptomatic bacteriuria and those uncovered by systematic screening and who received treatment following kidney transplantation are found.

TL;DR: The pooled analysis of the literature shows that AT remains a rare opportunistic infection with a nonspecific presentation and a variable course depending on the nature of the predisposing factor.